search
Back to results

Effectiveness of Various Smoking Cessation Therapies in Reducing Smoking in Adolescents - 1

Primary Purpose

Smoking Cessation, Tobacco Use Disorder

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Nicotine Replacement Therapies
Nicotine patch
Folic Acid
Sponsored by
National Institute on Drug Abuse (NIDA)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Smoking Cessation focused on measuring smoking addiction

Eligibility Criteria

13 Years - 18 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: At least 6 months of daily cigarette smoking No use of other tobacco products Motivated to reduce or quit smoking Not currently using medications to quit smoking Agree to use an effective form of contraception throughout the study Exclusion Criteria: People for whom use of nicotine replacement therapy or bupropion is medically inadvisable History of alcohol or drug abuse within 6 months of enrollment History of emotional problems (as assessed by the Adolescent Symptoms Inventory) within 6 months prior to enrollment Currently on an unstable dose of psychoactive medications Currently taking medications that may react with one of the treatment medications Pregnant

Sites / Locations

  • University of Minnesota

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

1

2

3

Arm Description

Nicotine patch

Nicotine gum

Folic acid

Outcomes

Primary Outcome Measures

Reduction in tobacco toxicant exposure

Secondary Outcome Measures

Motivation and self-efficacy to quit; measured at Weeks 5 and 17
Reduction in cigarettes per day
Smoking cessation

Full Information

First Posted
September 8, 2005
Last Updated
January 9, 2017
Sponsor
National Institute on Drug Abuse (NIDA)
search

1. Study Identification

Unique Protocol Identification Number
NCT00158171
Brief Title
Effectiveness of Various Smoking Cessation Therapies in Reducing Smoking in Adolescents - 1
Official Title
Interventions for Tobacco Dependent Adolescents
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
April 2002 (undefined)
Primary Completion Date
May 2004 (Actual)
Study Completion Date
May 2004 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute on Drug Abuse (NIDA)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Currently one in five high school students smokes. Smoking can harm adolescents well before they reach adulthood by causing a number of immediate, sometimes irreversible, health risks and problems. This study will compare the effectiveness of treatment with bupropion, a nicotine patch, or nicotine gum in supporting the reduction of smoking in adolescent smokers.
Detailed Description
Among adolescents, the short-term health effects of smoking include damage to the respiratory system, addiction to nicotine, and the associated risk of other drug use. Adolescents are at greater risk for long-term health problems because most young people who smoke regularly continue to smoke throughout adulthood. This study will compare the effectiveness of treatment with bupropion, a nicotine patch, or nicotine gum in supporting the reduction of smoking in adolescent smokers. The study will also assess whether reduction of smoking leads to continued involvement in treatment, less toxic cigarette exposure, and improved motivation to quit. This open-label study will last a total of 6 weeks. Baseline measurements will be taken twice a week at study visits for the first two weeks to assess vital signs and smoking behavior. Participants will aslo use a computerized device outside of study visits to monitor their own smoking habits. At Week 3, participants will be randomly assigned to receive bupropion, a nicotine patch, nicotine gum, or placebo. Participants will be asked to limit the frequency of their smoking to 75% of what it was during baseline. During Weeks 4, 5, and 6, participants will be expected to reduce smoking behavior to 50% of what it was at baseline. Customized doses of nicotine patches and nicotine gum, relative to the amount of cigarettes a participant smoked during baseline, will be dispensed weekly. Participants receiving bupropion or placebo will receive medication at each study visit and will take one pill daily. During treatment, study visits will occur once weekly. At each study visit, all participants will receive a 10- to 15-minute standardized behavioral therapy session aimed at supporting smoking reduction. Smoking habits and vital signs will be assessed and the effects of the treatments will be determined. There will be one follow-up visit 3 months post-intervention, at which time smoking status will be assessed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Smoking Cessation, Tobacco Use Disorder
Keywords
smoking addiction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
128 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Nicotine patch
Arm Title
2
Arm Type
Experimental
Arm Description
Nicotine gum
Arm Title
3
Arm Type
Placebo Comparator
Arm Description
Folic acid
Intervention Type
Drug
Intervention Name(s)
Nicotine Replacement Therapies
Other Intervention Name(s)
Nicorette
Intervention Description
Nicotine gum 2 & 4 mg dependent on baseline smoking rate
Intervention Type
Drug
Intervention Name(s)
Nicotine patch
Other Intervention Name(s)
Nicoderm
Intervention Description
21, 14 or 7 mg patch dependent on baseline smoking rate
Intervention Type
Dietary Supplement
Intervention Name(s)
Folic Acid
Intervention Description
400 mg
Primary Outcome Measure Information:
Title
Reduction in tobacco toxicant exposure
Time Frame
Weeks 2, 5 and 17
Secondary Outcome Measure Information:
Title
Motivation and self-efficacy to quit; measured at Weeks 5 and 17
Time Frame
Weeks 5 and 17
Title
Reduction in cigarettes per day
Time Frame
Weeks 5 and 17
Title
Smoking cessation
Time Frame
Weeks 5 and 17

10. Eligibility

Sex
All
Minimum Age & Unit of Time
13 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: At least 6 months of daily cigarette smoking No use of other tobacco products Motivated to reduce or quit smoking Not currently using medications to quit smoking Agree to use an effective form of contraception throughout the study Exclusion Criteria: People for whom use of nicotine replacement therapy or bupropion is medically inadvisable History of alcohol or drug abuse within 6 months of enrollment History of emotional problems (as assessed by the Adolescent Symptoms Inventory) within 6 months prior to enrollment Currently on an unstable dose of psychoactive medications Currently taking medications that may react with one of the treatment medications Pregnant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dorothy Hatsukami, Ph.D.
Organizational Affiliation
University of Minnesota
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Effectiveness of Various Smoking Cessation Therapies in Reducing Smoking in Adolescents - 1

We'll reach out to this number within 24 hrs